Developmental programming: Impact of prenatal testosterone excess on insulin sensitivity, adiposity, and free fatty acid profile in postpubertal female sheep

Endocrinology

Volumn 154, Issue 5, 2013, Pages 1731-1742

  Veiga Lopez, A ^a   Moeller, J ^a   Patel, D ^a   Ye, W ^c   Pease, A ^d   Kinns, J ^d   Padmanabhan, V ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Reproductive Sciences Program   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 TETRACOSENOIC ACID; ADRENIC ACID; ARACHIDONIC ACID; DIHOMOLINOLEIC ACID; DOCOSAPENTAENOIC ACID; ERUCIC ACID; FATTY ACID; GADOLEIC ACID; GLUCOSE; INSULIN; LINOLENIC ACID; MONOUNSATURATED FATTY ACID; MYRISTIC ACID; OLEIC ACID; PALMITIC ACID; PALMITOLEIC ACID; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; STEARIC ACID; TESTOSTERONE; UNCLASSIFIED DRUG;

ADAPTATION; ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FATTY ACID METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; SHEEP;

ADIPOSITY; ANIMALS; EMBRYONIC DEVELOPMENT; FATTY ACIDS, NONESTERIFIED; FEMALE; INSULIN RESISTANCE; METABOLOME; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SEX FACTORS; SEXUAL MATURATION; SHEEP; TESTOSTERONE;

EID: 84876764540     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2145     Document Type: Article

References (75)

1. Zawadki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications; 1992:377-384.
2. TheRotterdam ESHRE/ASRM-SponsoredPCOSConsensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-47.
3. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237-4245.
4. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95:2038-2049.
5. Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995; 10:2107-2111.
6. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2006;65:137-145.
7. Legro RS. The genetics of obesity. Lessons for polycystic ovary syndrome. Ann NY Acad Sci. 2000;900:193-202.
8. Barber TM, Golding SJ, Alvey C, et al. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:999-1004.
9. Manneras-Holm L, Leonhardt H, Kullberg J, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2011;96:E304-E311.
10. Dolfing JG, Stassen CM, van Haard PM, Wolffenbuttel BH, Schweitzer DH. Comparison of MRI-Assessed body fat content between lean women with polycystic ovary syndrome (PCOS) and matched controls: less visceral fat with PCOS. Hum Reprod. 2011; 26:1495-1500.
11. Padmanabhan V, Veiga-Lopez A. Developmental origin of reproductive and metabolic dysfunctions: androgenic versus estrogenic reprogramming. Semin Reprod Med. 2011;29:173-186.
12. Padmanabhan V, Veiga-Lopez A. 2012 Sheep models of polycystic ovary syndrome phenotype [published online October 16, 2012]. Mol Cell Endocrinol. doi:10.1016/j.mce.2012.10.005.
13. Dumesic DA, Abbott DH, Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord. 2007;8:127-141.
14. Padmanabhan V, Veiga-Lopez A, Abbott DH, Recabarren SE, Herkimer C. Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females. Endocrinology. 2010;151:595-605.
15. Nada SE, Thompson RC, Padmanabhan V. Developmental programming: differential effects of prenatal testosterone excess on insulin target tissues. Endocrinology. 2010;151:5165-5173.
16. Cnop M, Landchild MJ, Vidal J, et al. The concurrent accumulation of intra-Abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations : distinct metabolic effects of two fat compartments. Diabetes. 2002; 51:1005-1015.
17. Wagenknecht LE, Langefeld CD, Scherzinger AL, et al. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes. 2003;52: 2490-2496.
18. Eisner JR, Dumesic DA, Kemnitz JW, Abbott DH. Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J Clin Endocrinol Metab. 2000;85:1206-1210.
19. Eisner JR, Dumesic DA, Kemnitz JW, Colman RJ, Abbott DH. Increased adiposity in female rhesus monkeys exposed to androgen excess during early gestation. Obes Res. 2003;11:279-286.
20. Demissie M, Lazic M, Foecking EM, Aird F, Dunaif A, Levine JE. Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am J Physiol Endocrinol Metab. 2008; 295:E262-E268.
21. Faulds G, Ryden M, Ek I, Wahrenberg H, Arner P. Mechanisms behind lipolytic catecholamine resistance of subcutaneous fat cells in the polycystic ovarian syndrome. J Clin Endocrinol Metab. 2003; 88:2269-2273.
22. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-Analysis. Fertil Steril. 2011;95:1073-1079.e1071-e1011.
23. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab. 1999;84:137-144.
24. Rendell M, Hulthen UL, Tornquist C, Groop L, Mattiasson I. Relationship between abdominal fat compartments and glucose and lipid metabolism in early postmenopausal women. J Clin Endocrinol Metab. 2001;86:744-749.
25. Nguyen-Duy TB, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat and liver fat are independent predictors of metabolic risk factors in men. Am J Physiol Endocrinol Metab. 2003;284:E1065-E1071.
26. Koutsari C, Jensen MD. Thematic review series: patient-oriented research. Free fatty acid metabolism in human obesity. J Lipid Res. 2006;47:1643-1650.
27. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46:3-10.
28. Frayn KN. Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc. 2001;60:375-380.
29. Abbott DH, Eisner JR, Goodfriend TL, et al. Leptin and total free fatty acids are elevated in the circulation of prenatally androgenized female rhesus monkeys. Program of the 84th Annual Meeting of The Endocrine Society, San Francisco, California, 2002, Abstract P2-329, p. 398.
30. Manikkam M, Crespi EJ, Doop DD, et al. Fetal programming: pre-natal testosterone excess leads to fetal growth retardation and postnatal catch-up growth in sheep. Endocrinology. 2004;145:790-798.
31. Sano H, Matsunobu S, Abe T, Terashima Y. Combined effects of diet and cold exposure on insulin responsiveness to glucose and tissue responsiveness to insulin in sheep. J Anim Sci. 1992;70:3514-3520.
32. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
33. Tserng KY, Kliegman RM, Miettinen EL, Kalhan SC. A rapid, simple, and sensitive procedure for the determination of free fatty acids in plasma using glass capillary column gas-liquid chromatography. J Lip Res. 1981;22:852-858.
34. Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes. 2001;50:2444-2450.
35. Recabarren SE, Padmanabhan V, Codner E, et al. Postnatal developmental consequences of altered insulin sensitivity in female sheep treated prenatally with testosterone. Am J Physiol Endocrinol Metab. 2005;289:E801-E806.
36. Roland AV, Nunemaker CS, Keller SR, Moenter SM. Prenatal androgen exposure programs metabolic dysfunction in female mice. J Endocrinol. 2010;207:213-223.
37. Alexanderson C, Eriksson E, Stener-Victorin E, et al. Postnatal testosterone exposure results in insulin resistance, enlarged mesenteric adipocytes, and an atherogenic lipid profile in adult female rats: comparisons with estradiol and dihydrotestosterone. Endocrinology. 2007;148:5369-5376.
38. Nilsson C, Niklasson M, Eriksson E, Bjorntorp P, Holmang A. Imprinting of female offspring with testosterone results in insulin resistance and changes in body fat distribution at adult age in rats. J Clin Invest. 1998;101:74-78.
39. Manneras L, Cajander S, Holmang A, et al. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology. 2007;148:3781-3791.
40. Reiling BA, Drackley JK, Grum LR, Berger LL. Effects of prenatal androgenization and lactation on adipose tissue metabolism in finishing single-calf heifers. J Anim Sci. 1997;75:1504-1513.
41. Abbott DH, Goodfriend TL, Dunaif A, Muller SJ, Dumesic DA, Tarantal AF. Increased body weight and enhanced insulin sensitivity in infant female rhesus monkeys exposed to androgen excess during early gestation. Program of the 89th Annual Meeting of The Endocrine Society, Toronto, Canada, 2007, Abstract, P2-348, p. 417.
42. Acien P, Quereda F, Matallin P, et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril. 1999;72:32-40.
43. Vrbikova J, Cibula D, Dvorakova K, et al. Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:2942-2945.
44. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18:774-800.
45. Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res. 2001;56:295-308.
46. Barber TM, Franks S. The link between polycystic ovary syndrome and both type 1 and type 2 diabetes mellitus: what do we know today? Womens Health (Lond Engl). 2012;8:147-154.
47. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:E15-E26.
48. Nada S, Thompson RC, Padmanabhan V. Developmental programming: differential effects of prenatal testosterone excess on insulin target tissues. Program of the 91st Annual Meeting of The Endocrine Society, Washington, DC, 2009 Abstract P1-273, p. 22.
49. Abbott DH, Barnett DK, Levine JE, et al. Endocrine antecedents of polycystic ovary syndrome in fetal and infant prenatally androgenized female rhesus monkeys. Biol Reprod. 2008;79:154-163.
50. Dumesic DA, Abbott DH, Eisner JR, Goy RW. Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood. Fertil Steril. 1997;67:155-163.
51. Wade GN, Gray JM, Bartness TJ. Gonadal influences on adiposity. Int J Obes. 1985;9(suppl 1):83-92.
52. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-α knockout mice. Proc Natl Acad Sci USA. 2000;97:12729-12734.
53. Singh R, Artaza JN, Taylor WE, et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with -catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology. 2006;147:141-154.
54. Yeh S, Tsai MY, Xu Q, et al. Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci USA. 2002;99:13498-13503.
55. Muller G. Let's shift lipid burden -from large to small adipocytes. Eur J Pharmacol. 2011;656:1-4.
56. Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia. 2000;43:1498-1506.
57. Stern JS, Batchelor BR, Hollander N, Cohn CK, Hirsch J. Adiposecell size and immunoreactive insulin levels in obese and normalweight adults. Lancet. 1972;2:948-951.
58. Farnier C, Krief S, Blache M, et al. Adipocyte functions are modulated by cell size change: potential involvement of an integrin/ERK signalling pathway. Int J Obes Relat Metab Disord. 2003;27:1178-1186.
59. Solyom A. Effect of androgens on serum lipids and lipoproteins. Lipids. 1972;7:100-105.
60. Vessby B, Tengblad S, Lithell H. Insulin sensitivity is related to the fatty acid composition of serum lipids and skeletal muscle phospholipids in 70-year-old men. Diabetologia. 1994;37:1044-1050.
61. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med. 2001;11:170-176.
62. Leat WM, Ford EJ. Utilization of free fatty acids by starved and pregnant sheep. Biochem J. 1966;101:317-322.
63. Goeransson G. The metabolism of fatty acids in the rat. IV. Stearic acid. Acta Physiol Scand. 1965;63:423-427.
64. Goeransson G. The metabolism of fatty acids in the rat. V. Palmitoleic acid. Acta Physiol Scand. 1965;63:428-433.
65. Escobar-Morreale HF, Samino S, Insenser M, et al. Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS. Clin Chem. 2012;58: 999-1009.
66. Samocha-Bonet D, Chisholm DJ, Tonks K, Campbell LV, Greenfield Jr. Insulin-sensitive obesity in humans -A 'favorable fat' phenotype? Trends Endocrinol Metab. 2012;23:116-124.
67. Steimer T, Driscoll P. Inter-individual vs line/strain differences in psychogenetically selected Roman High-(RHA) and Low-(RLA) Avoidance rats: neuroendocrine and behavioural aspects. Neurosci Biobehav Rev. 2005;29:99-112.
68. Wells JC. Thrift: a guide to thrifty genes, thrifty phenotypes and thrifty norms. Int J Obes. 2009;33:1331-1338.
69. Steckler TL, Herkimer C, Dumesic DA, Padmanabhan V. Developmental programming: excess weight gain amplifies the effects of prenatal testosterone excess on reproductive cyclicity -implication for polycystic ovary syndrome. Endocrinology. 2009;150:1456-1465.
70. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 1992;41:1257-1266.
71. Rosenbaum D, Haber RS, Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol. 1993;264:E197-E202.
72. Jungheim ES, Macones GA, Odem RR, et al. Associations between free fatty acids, cumulus oocyte complex morphology and ovarian function during in vitro fertilization. Fertil Steril. 2011;95:1970-1974.
73. Ortega HH, Rey F, VelazquezMM,Padmanabhan V. Developmental programming: effect of prenatal steroid excess on intraovarian components of insulin signaling pathway and related proteins in sheep. Biol Reprod. 2010;82:1065-1075.
74. Ortega HH, Salvetti NR, Padmanabhan V. Developmental programming: prenatal androgen excess disrupts ovarian steroid receptor balance. Reproduction. 2009;137:865-877.
75. Steckler TL, Roberts EK, Doop DD, Lee TM, Padmanabhan V. Developmental programming in sheep: administration of testosterone during 60-90 days of pregnancy reduces breeding success and pregnancy outcome. Theriogenology. 2007;67:459-467.